Medical genetic test reporting for cystic fibrosis (ΔF508) and factor V Leiden in North American laboratories

被引:10
作者
Andersson, HC
Krousel-Wood, MA
Jackson, KE
Rice, J
Lubin, IM
机构
[1] Tulane Univ, Sch Med, Human Genet Program, Hayward Genet Ctr, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Gen Prevent Med Residency Program, New Orleans, LA 70112 USA
[3] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA
[4] Ctr Dis Control & Prevent, PHPPO, DLS, Off Genet Testing, Atlanta, GA USA
关键词
cystic fibrosis; factor V Leiden; genetic tests; test result reporting;
D O I
10.1097/00125817-200209000-00002
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Physicians are ordering an increasing number of genetic tests. Results and additional information provided in the test result report are vital to the physician in making appropriate patient management decisions. Because variability in test result reports can impact patient care, we sought to determine whether variations exist in test reports for cystic fibrosis (CF) and factor V Leiden (fVL) with specific comparison to professional guidelines and recommendations. Methods: A cross-sectional study design analyzing for the presence of 16 critical elements in CF reports and 12 critical elements in fVL reports solicited from United States and Canadian laboratories. Results: Of 44 laboratories performing CF testing and 72 laboratories performing fVL testing, 64% responded. For CF reports, 21% included ethnicity, 64% described methodology, and 61% discussed genetic counseling. For fVL reports, 80% described methodology and 52% discussed the need for genetic counseling in mutation-positive reports. Conclusions: Variability exists in report content among North American laboratories performing CF and fVL testing. Many reports lack information deemed critical by professional guidelines and recommendations.
引用
收藏
页码:324 / 327
页数:4
相关论文
共 11 条
[1]  
CUTTING GR, 1997, NIH CONS DEV C GEN T
[2]   The use and interpretation of commercial APC gene testing for familial adenomatous polyposis [J].
Giardiello, FM ;
Brensinger, JD ;
Petersen, GM ;
Luce, MC ;
Hylind, LM ;
Bacon, JA ;
Booker, SV ;
Parker, RD ;
Hamilton, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (12) :823-827
[3]   Diversity of cystic fibrosis mutation-screening practices [J].
Grody, WW ;
Desnick, RJ ;
Carpenter, NJ ;
Noll, WW .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (05) :1252-1254
[4]   Cystic fibrosis population carrier screening: Here at last-Are we ready? [J].
Grody, WW ;
Desnick, RJ .
GENETICS IN MEDICINE, 2001, 3 (02) :87-90
[5]   Report card on molecular genetic testing - Room for improvement? [J].
Grody, WW ;
Pyeritz, RE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (09) :845-847
[6]   Predictive genetic testing: From basic research to clinical practice [J].
Holtzman, NA ;
Murphy, PD ;
Watson, MS ;
Barr, PA .
SCIENCE, 1997, 278 (5338) :602-605
[7]   A MUTATION IN CFTR PRODUCES DIFFERENT PHENOTYPES DEPENDING ON CHROMOSOMAL BACKGROUND [J].
KIESEWETTER, S ;
MACEK, M ;
DAVIS, C ;
CURRISTIN, SM ;
CHU, CS ;
GRAHAM, C ;
SHRIMPTON, AE ;
CASHMAN, SM ;
TSUI, LC ;
MICKLE, J ;
AMOS, J ;
HIGHSMITH, WE ;
SHUBER, A ;
WITT, DR ;
CRYSTAL, RG ;
CUTTING, GR .
NATURE GENETICS, 1993, 5 (03) :274-278
[8]   Quality assurance in molecular genetic testing laboratories [J].
McGovern, MM ;
Benach, MO ;
Wallenstein, S ;
Desnick, RJ ;
Keenlyside, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (09) :835-840
[9]  
*NAT COMM CLIN LAB, 2000, MM1A CCLS NAT COMM C, V17
[10]  
*U WASH CHILDR HLT, 2001, GEN MED GEN INF RES